Terms: = Ovarian cancer AND HOXD11, ENSG00000128713, 3237
6 results:
1. Association of guideline-concordant care with survival, health care utilization, and costs among older women with advanced epithelial ovarian cancer.
Kamat S; Brown BR; Hume A; Vyas A
Am J Manag Care; 2023 Oct; 29(10):e292-e298. PubMed ID: 37870550
[TBL] [Abstract] [Full Text] [Related]
2. The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature.
Wang M; Yin Z; Miao J; Wu Y
Arch Gynecol Obstet; 2022 Jan; 305(1):49-54. PubMed ID: 34115181
[TBL] [Abstract] [Full Text] [Related]
3. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract] [Full Text] [Related]
4. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract] [Full Text] [Related]
5. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and hoxd11 in ovarian cancers.
Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
[TBL] [Abstract] [Full Text] [Related]
6. Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging.
Chen M; Wang WC; Zhou C; Zhou NN; Cai K; Yang ZH; Zhao WF; Li SY; Li GZ
Chin Med Sci J; 2006 Dec; 21(4):270-5. PubMed ID: 17249204
[TBL] [Abstract] [Full Text] [Related]
